Hydrogen-rich water ameliorates neuropathological impairments in a mouse model of Alzheimer’s disease through reducing neuroinflammation and modulating intestinal microbiota.
Yi-Tong Lin, Qing-Qing Shi, Lei Zhang, Cai-Ping Yue, Zhi-Jun He, Xue-Xia Li, Qian-Jun He, Qiong Liu, Xiu-Bo Du · Neural regeneration research · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In contrast, HRW treatment improved these emotional disorders in 3×Tg-AD mice, with an increased frequency of grid crossings and rearing and a decreased frequency of defecation ( P < 0.05; Figure 1E ). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in mice. In contrast, HRW treatment improved these emotional disorders in 3×Tg-AD mice, with an increased frequency of grid crossings and rearing and a decreased frequency of defecation ( P < 0.05; Figure 1E ).
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 8 µM H₂ (≈0.016 mg/L); reported treatment duration: 30 days. In contrast, HRW treatment improved these emotional disorders in 3×Tg-AD mice, with an increased frequency of grid crossings and rearing and a decreased frequency of defecation ( P < 0.05; Figure 1E ). The authors concluded that hydrogen-rich water is an effective hydrogen donor that can treat Alzheimer's disease. Hydrogen-rich water improved brain energy metabolism disorders and intestinal flora imbalances and reduced inflammatory reactions. In the present study, hydrogen was effective in reducing metabolic dysfunction and neuroinflammation in AD by manipulating the bioenergetic pathway.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 8 µM H₂ (≈0.016 mg/L). The reported treatment duration was 30 days.
Limitations and Safety
Reported limitations: Stereotactic injection has been previously used as an invasive method of administering active hydrogen, but this method has limitations in clinical practice.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.